Document is current
Any future updates will be listed below
-
Authors
Heard, Amanda https://orcid.org/0000-0002-7150-7998
Landmann, Jack H.
Hansen, Ava R. https://orcid.org/0000-0003-1908-6433
Papadopolou, Alkmini
Hsu, Yu-Sung
Selli, Mehmet Emrah https://orcid.org/0000-0002-3478-8970
Warrington, John M. https://orcid.org/0000-0001-6066-5491
Lattin, John
Chang, Jufang
Ha, Helen
Haug-Kroeper, Martina
Doray, Balraj https://orcid.org/0000-0003-3347-5013
Gill, Saar
Ruella, Marco https://orcid.org/0000-0003-4301-5811
Hayer, Katharina E.
Weitzman, Matthew D. https://orcid.org/0000-0001-9713-167X
Green, Abby M.
Fluhrer, Regina https://orcid.org/0000-0002-9778-4643
Singh, Nathan https://orcid.org/0000-0002-0350-7574
-
Funding
Funding for this research was provided by:
Be The Match Foundation
- License Information
-
More Information
Article History
Received: 3 September 2021
Accepted: 31 May 2022
First Online: 11 June 2022
Competing interests
: N.S. holds patent 15/567,156 (Methods for Improving the Efficacy and Expansion of Chimeric Antigen Receptor-Expressing Cells); N.S., M.R., and S.G. hold patent 17/058,163 (Combination Therapy with Chimeric Antigen Receptor Therapies); M.R. and S.G. hold patent 16/256,731(CD20 therapies, CD22 therapies, and combination therapies with CD19 chimeric antigen receptor-expressing cells) which are related to investigational and commercial CAR T cell products. The remaining authors declare no competing interests.
